Actinium Pharmaceuticals (ATNM) Q2 2026 earnings summary

Executive summary

• Achieved net income of $27.9 million for Q2 2026, a $34.8 million improvement year-over-year, driven by recognition of $35 million previously deferred license revenue from Immedica after expiration of their claim rights.

• Research and development expenses increased slightly in Q2 2026 due to higher preclinical and clinical costs, while general and administrative expenses decreased due to lower headcount and stock-based compensation.

• No commercial product revenue was recorded; all revenue recognized was from the Immedica license agreement.

Financial highlights

• Q2 2026 revenue: $35 million (vs. $0 in Q2 2025), entirely from license revenue recognition.

• Net income for Q2 2026: $27.9 million (vs. net loss of $6.9 million in Q2 2025).

• Six months ended June 30, 2026: revenue $35 million, net income $22.4 million (vs. net loss of $22.8 million in prior year period).

• Operating expenses for Q2 2026: $7.4 million (R&D $5.4M, G&A $2.1M).

• Cash, cash equivalents, and restricted cash at June 30, 2026: $36.8 million.

• Stockholders’ equity increased to $30.3 million as of June 30, 2026.

Outlook and guidance

• Existing resources expected to fund operations for more than 12 months from the report date.

• Ongoing and planned clinical trials for ATNM-400, Actimab-A, and Iomab-ACT, with data expected in late 2026 and 2027.

• Actively seeking strategic partners for Actimab-A and Iomab-B to advance registrational trials.